TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - NOVARTIS N Stock

Certificat

DE000SF4DL87

Market Closed - Boerse Frankfurt Warrants 03:41:24 2024-06-06 pm EDT
4.18 EUR +1.21% Intraday chart for TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - NOVARTIS N
Current month+5.30%
1 month+17.13%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-06-06 4.17 +0.97%
24-06-05 4.13 +2.74%
24-06-04 4.02 +2.81%
24-06-03 3.91 -1.26%
24-05-31 3.96 +3.66%

Real-time Boerse Frankfurt Warrants

Last update June 06, 2024 at 03:41 pm EDT

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellCALL
Underlying NOVARTIS AG
IssuerLogo Issuer Société Générale Société Générale
WKN SF4DL8
ISINDE000SF4DL87
Date issued 2021-09-09
Strike 53.79 CHF
Maturity Unlimited
Parity 10 : 1
Emission price 2.37
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 4.25
Lowest since issue 1.53

Company Profile

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Sector
-
More about the company

Ratings for Novartis AG

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: Novartis AG

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
106.5 USD
Average target price
110.1 USD
Spread / Average Target
+3.40%
Consensus